KR20230079514A - 암 면역요법용 dna 백신을 제조하기 위한 방법 - Google Patents
암 면역요법용 dna 백신을 제조하기 위한 방법 Download PDFInfo
- Publication number
- KR20230079514A KR20230079514A KR1020237018125A KR20237018125A KR20230079514A KR 20230079514 A KR20230079514 A KR 20230079514A KR 1020237018125 A KR1020237018125 A KR 1020237018125A KR 20237018125 A KR20237018125 A KR 20237018125A KR 20230079514 A KR20230079514 A KR 20230079514A
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- ser
- val
- pro
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020267008900A KR20260047288A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550 | 2016-07-13 | ||
| EP16001550.9 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
| KR1020197002050A KR20190027834A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197002050A Division KR20190027834A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267008900A Division KR20260047288A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230079514A true KR20230079514A (ko) | 2023-06-07 |
Family
ID=56418345
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237018125A Ceased KR20230079514A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
| KR1020197002050A Ceased KR20190027834A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
| KR1020267008900A Pending KR20260047288A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197002050A Ceased KR20190027834A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
| KR1020267008900A Pending KR20260047288A (ko) | 2016-07-13 | 2017-07-12 | 암 면역요법용 dna 백신을 제조하기 위한 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3484503A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7098599B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20230079514A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109475614A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017295004B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019000657A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028549A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263568A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019000415A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019100079A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201811258UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018011289A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190117603A (ko) | 2017-02-17 | 2019-10-16 | 백심 아게 | 신규 vegfr-2 표적화 면역요법상 접근법 |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| CA3176812A1 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| US20210213121A1 (en) * | 2018-09-05 | 2021-07-15 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| AU2021208400A1 (en) | 2020-01-13 | 2022-08-11 | Vaximm Ag | Salmonella-based DNA vaccines in combination with an antibiotic |
| US20250340919A1 (en) * | 2022-06-30 | 2025-11-06 | Shimadzu Corporation | Method for Preparing Analysis of Microorganisms, and Method for Analyzing Microorganisms |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013091898A1 (en) | 2011-12-22 | 2013-06-27 | Vaximm Ag | Method for producing high yield attenuated salmonella strains |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2714071T (lt) * | 2011-05-24 | 2019-10-10 | Biontech Rna Pharmaceuticals Gmbh | Individualizuotos vakcinos nuo vėžio |
| SG11201500054QA (en) * | 2012-07-05 | 2015-03-30 | Vaximm Ag | Dna vaccine for use in pancreatic cancer patients |
| DK2988762T3 (en) * | 2013-04-25 | 2018-07-16 | Vaximm Ag | SALMONELLA-BASED VECTORS FOR CANCER IMMUNITY TARGET TARGETED WILMS 'TUMORGEN WT1 |
| PL3082850T3 (pl) | 2013-12-18 | 2020-01-31 | Vaximm Gmbh | Celowana szczepionka DNA MSLN w immunoterapii nowotworu |
| JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
-
2017
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 KR KR1020267008900A patent/KR20260047288A/ko active Pending
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013091898A1 (en) | 2011-12-22 | 2013-06-27 | Vaximm Ag | Method for producing high yield attenuated salmonella strains |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019000657A2 (pt) | 2019-04-24 |
| KR20190027834A (ko) | 2019-03-15 |
| IL263568A (en) | 2019-01-31 |
| WO2018011289A1 (en) | 2018-01-18 |
| JP2019521154A (ja) | 2019-07-25 |
| JP2022097591A (ja) | 2022-06-30 |
| RU2019100079A (ru) | 2020-08-13 |
| US10821163B2 (en) | 2020-11-03 |
| CN109475614A (zh) | 2019-03-15 |
| US11590215B2 (en) | 2023-02-28 |
| JP7098599B2 (ja) | 2022-07-11 |
| AU2017295004A1 (en) | 2019-01-03 |
| EP3484503A1 (en) | 2019-05-22 |
| SG11201811258UA (en) | 2019-01-30 |
| US20220072112A1 (en) | 2022-03-10 |
| US20190183996A1 (en) | 2019-06-20 |
| CA3028549A1 (en) | 2018-01-18 |
| AU2017295004B2 (en) | 2020-08-13 |
| KR20260047288A (ko) | 2026-04-07 |
| MX2019000415A (es) | 2019-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017295004B2 (en) | Process for the production of a DNA vaccine for cancer immunotherapy | |
| KR102090612B1 (ko) | 췌장암 환자용 dna 백신 | |
| CN107995868B (zh) | 用于联合治疗的vegfr-2靶向dna疫苗 | |
| KR20190125481A (ko) | 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신 | |
| AU2018222777B9 (en) | Novel VEGFR-2 targeting immunotherapy approach | |
| JP2024167172A (ja) | 併用療法用dnaワクチンを標的とするネオアンチゲン | |
| CN109906087A (zh) | 用于联合治疗的wt1靶向dna疫苗 | |
| KR20220161444A (ko) | 새로운 살모넬라-기반의 코로나바이러스 백신 | |
| RU2759227C2 (ru) | ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов | |
| KR20220128638A (ko) | 항생제와 조합되는 살모넬라-기반의 dna 백신 | |
| CN120944823A (zh) | 特异性结合Claudin18.2的嵌合抗原受体免疫细胞及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B17 | Application discontinued following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B17-REX-PX0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0601 | Decision of rejection after re-examination |
St.27 status event code: N-2-6-B10-B17-rex-PX0601 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PJ0201 | Trial against decision of rejection |
St.27 status event code: A-3-3-V10-V11-apl-PJ0201 |
|
| V11 | Administrative appeal requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE) |